Mallinckrodt Plans New Research Facility

Published Online: Wednesday, December 1, 2004

Mallinckrodt's expansion and relocation of its pharmaceutical research and development laboratory operations are under way. The 65,000-sq-ft facility, located on Marshall Road in Webster Groves, St. Louis, Mo, is slated for completion in the spring of 2005. The renovation will allow for a significant increase in Mallinckrodt's pharmaceutical research capabilities in St. Louis. It also represents the health care company's commitment to ongoing development of innovative generic drug products for human use.

A large segment of the research scientists currently working at Mallinckrodt's St. Louis production plant will relocate to the new facility upon its completion. Furthermore, the company anticipates adding 20 to 25 researchers over the next year. When up and running, the facility will house about 100 individuals. The existing St. Louis research facilities will be redesigned to meet the expanding needs of the company's chemical business.

Latest Articles
The FDA has approved Boehringer Ingelheim’s oral direct thrombin inhibitor dabigatran etexilate mesylate (Pradaxa) for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who have had hip replacement surgery.
As a result of implementation difficulties, the FDA announced that it will extend the pharmacy certification deadline for the clozapine risk evaluation and mitigation strategy program.
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Latest Issues